Glenmede Investment Management, LP Acadia Pharmaceuticals Inc Transaction History
Glenmede Investment Management, LP
- $19.8 Trillion
- Q2 2025
A detailed history of Glenmede Investment Management, LP transactions in Acadia Pharmaceuticals Inc stock. As of the latest transaction made, Glenmede Investment Management, LP holds 2,669 shares of ACAD stock, worth $59,705. This represents 0.0% of its overall portfolio holdings.
Number of Shares
2,669Holding current value
$59,705% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding ACAD
# of Institutions
353Shares Held
164MCall Options Held
811KPut Options Held
334K-
Baker Bros. Advisors LP New York, NY42.9MShares$960 Million9.38% of portfolio
-
Vanguard Group Inc Valley Forge, PA15.3MShares$341 Million0.01% of portfolio
-
Black Rock Inc. New York, NY12.1MShares$270 Million0.0% of portfolio
-
Rtw Investments, LP New York, NY9MShares$201 Million2.98% of portfolio
-
State Street Corp Boston, MA6.18MShares$138 Million0.01% of portfolio
About ACADIA PHARMACEUTICALS INC
- Ticker ACAD
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 161,843,008
- Market Cap $3.62B
- Description
- ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's p...